A Shamas-Din - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

A Shamas-Din

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Oncogene|July 31, 2009

Bid: a Bax-like BH3 proteinL P Billen, A Shamas-Din, D W Andrews

Cell Death & Disease|June 6, 2014

Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBidA Shamas-Din, D Satsoura, O Khan, et al.

Cell Death & Disease|July 10, 2015

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Oncogene|July 31, 2009

Bid: a Bax-like BH3 proteinL P Billen, A Shamas-Din, D W Andrews

Cell Death & Disease|June 6, 2014

Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBidA Shamas-Din, D Satsoura, O Khan, et al.

Cell Death & Disease|July 10, 2015

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosingZ Wang, P Dove, X Wang, et al.

Pageof 1